ACM
TRAW icon

ADAR1 Capital Management’s Traws Pharma TRAW Stock Holding History

ADAR1 Capital Management’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$282K Sell
154,098
-333
-0.2% -$626 0.02% 242
2025
Q4 		$175K Buy
+154,431
New +$343K 0.01% 232

Other funds holding TRAW

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $478M AUM 50.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

ADAR1 Capital Management's TRAW Position: Q1 2026 in Review

ADAR1 Capital Management reduced its Traws Pharma (TRAW) stake by 0.22% in Q1 2026, selling an estimated $626 and leaving 154,098 shares worth $282K. The position accounts for 0.02% of the portfolio, ranked #242.

ADAR1 Capital Management first reported a position in TRAW in Q4 2025 and has held it in 2 quarters since. 28 funds tracked by Wall St. Rank hold TRAW as of Q1 2026.

  • ADAR1 Capital Management held 154,098 shares of Traws Pharma worth $282K as of Q1 2026.
  • ADAR1 Capital Management sold 333 Traws Pharma shares in Q1 2026, an estimated $626.
  • Traws Pharma made up 0.02% of ADAR1 Capital Management's portfolio in Q1 2026, its #242 holding.
  • ADAR1 Capital Management first reported a position in Traws Pharma in Q4 2025 and has held it in 2 quarters since.
  • 28 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.